Table 7 Overview of published clinical data on hypofractionation in prostate cancer
From: Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment
References | Fractions | Fraction size | Total dose | weeks | NTD2 for α/β | Acute toxicity | |||
|---|---|---|---|---|---|---|---|---|---|
α/β = 1.5 | α/β =3 | α/β =10 | GI (%) | GU (%) | |||||
Livsey et al. [12] | 6 | 6 | 36 | 3 | 77.1 | 64.8 | 48 | ||
Kupelian et al. [9] | 28 | 2.5 | 70 | 5.5 | 80 | 77 | 72.9 | 19 | 15 |
Soete et al. [15] | 16 | 3.5 | 56 | 4 | 80 | 72.8 | 63 | 38 | 39 |
Madsen et al. [10] | 5 | 6.7 | 33.5 | 1 | 78.5 | 65 | 46.6 | 22 | 13 |
Pollack et al. [13] | 26 | 2.7 | 70.2 | 5 | 84.2 | 80.5 | 74.3 | 18 | 48 |
Martin et al. [14] | 20 | 3 | 60 | 4 | 77.1 | 72 | 65 | 12 | 25 |
FAMEMA trial (present study) | 23 | 3 | 69 | 4.5 | 88.7 | 83 | 76 | 20.5% | 23.2% |